The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34222
Abstract: Two Janus‐associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate‐risk and high‐risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease… read more here.
Keywords: clinical dilemma; jaki; inhibitor; myelofibrosis ... See more keywords
Systemic inhibition of Janus kinase induces browning of white adipose tissue and ameliorates obesity-related metabolic disorders.
Sign Up to like & getrecommendations! Published in 2018 at "Biochemical and biophysical research communications"
DOI: 10.1016/j.bbrc.2018.05.131
Abstract: Browning of white adipose tissue is a promising strategy to tackle obesity. Recently, Janus kinase (JAK) inhibition was shown to induce white-to-brown metabolic conversion of adipocytes in vitro; however effects of JAK inhibition on browning and… read more here.
Keywords: inhibition; white adipose; adipose tissue; obesity ... See more keywords
Increasing Antitumor Activity of JAK Inhibitor by Simultaneous Blocking Multiple Survival Signaling Pathways in Human Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2019 at "Translational Oncology"
DOI: 10.1016/j.tranon.2019.05.003
Abstract: Many signaling pathways, including the JAK/STAT3 pathway, are aberrantly activated and associated with ovarian cancer growth and progression. However, inhibition of STAT3 pathway alone was not sufficient to effectively block human ovarian cancer cell survival… read more here.
Keywords: jaki; inhibitor; ovarian cancer; activity ... See more keywords
State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2020.1822325
Abstract: ABSTRACT Introduction Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults. In the past decade, many treatments have emerged to expand the therapeutic armamentarium of rheumatologists. Among emerging treatments, Janus Kinase inhibitors… read more here.
Keywords: jak; approved emerging; rheumatoid arthritis; arthritis ... See more keywords
Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2022.2039630
Abstract: ABSTRACT Introduction To date, four Janus kinase inhibitors (JAKis) are licensed for the treatment of rheumatoid arthritis (RA) and/or psoriatic arthritis (PsA) in North America and/or Europe: tofacitinib, baricitinib, upadacitinib, and filgotinib. Most DMARDs have… read more here.
Keywords: jak inhibitors; jaki; safety jak; risk ... See more keywords
Janus kinase inhibitors alter NK cells phenotype and inhibit their antitumor capacity.
Sign Up to like & getrecommendations! Published in 2022 at "Rheumatology"
DOI: 10.1093/rheumatology/keac710
Abstract: OBJECTIVE Janus kinase inhibitors (JAKi) are efficacious in rheumatoid arthritis (RA) but concerns regarding the risk of cancer associated with their exposure have recently emerged. Given the role of NK cells in antitumor response, we… read more here.
Keywords: kinase inhibitors; jaki; impact; janus kinase ... See more keywords
P126 Cycling of JAK inhibitors: Experience from a large UK teaching hospital
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.167
Abstract: JAK inhibitors (JAKi) are relatively recently licenced for treatment of inflammatory arthritis. Therefore, long term data regarding outcomes for patients cycling through multiple JAKi are lacking. However, one recent international cohort study (Pombo Suarez et… read more here.
Keywords: jak inhibitors; jaki; initial jaki; side ... See more keywords
E072 Real-world single-centre experience of JAK inhibitor use in RA
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.321
Abstract: The use of Janus Kinase Inhibitors (JAKi) has been gradually increasing overtime in the management of rheumatoid arthritis (RA) and other inflammatory arthritis and these appeal to patients. being oral agents. Nevertheless, rheumatologists have become… read more here.
Keywords: jaki; side effects; centre; treatment ... See more keywords
POS0207 REAL-WORLD RETENTION OF JAK INHIBITORS IS LONGER THAN BDMARDS IN RHEUMATOID ARTHRITIS
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.705
Abstract: Biological disease modifying anti-rheumatic drugs (bDMARDs) and Janus Kinase inhibitors (JAKi) are both recommended post conventional synthetic disease modifying anti-rheumatic drug (csDMARD) therapy failure in active rheumatoid arthritis (RA), but the data on long-term durability… read more here.
Keywords: therapy; duration; jaki; age ... See more keywords
After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries
Sign Up to like & getrecommendations! Published in 2022 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/ard-2022-222835
Abstract: Objectives The expanded therapeutic arsenal in rheumatoid arthritis (RA) raises new clinical questions. The objective of this study is to compare the effectiveness of cycling Janus kinase inhibitors (JAKi) with switching to biologic disease-modifying antirheumatic… read more here.
Keywords: jak pot; jaki; failure; pot collaboration ... See more keywords
Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study
Sign Up to like & getrecommendations! Published in 2022 at "RMD Open"
DOI: 10.1136/rmdopen-2022-002614
Abstract: Objective To determine the risk of malignancy in Korean patients with rheumatoid arthritis (RA) receiving Janus kinase inhibitors (JAKis) compared with tumour necrosis factor inhibitors (TNFis). Methods A retrospective cohort of patients with RA initiating… read more here.
Keywords: jaki; korean patients; malignancy; tnfi ... See more keywords